Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775722 · ClinicalTrials.gov registry record · NA
Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
A NA study, sponsored by University of California, Irvine.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT01775722: Completed NA study, sponsored by University of California, Irvine.
NCT01775722 is a NA study that has completed, run by University of California, Irvine. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01775722, a NA study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Port wine stain Birthmark is a congenital, progressive vascular malformation of human skin. However, even though the pulsed dye laser is considered as the treatment of choice for Port wine stain Birthmark the degree of fading can remain variable and unpredictable after laser treatment.
Primary Outcome
Port Wine Stain blood volume fractions in the skin before (fB1), and 8 weeks after (fB2) treatment will be determined using the corresponding visual reflectance spectra measured at the treatment sites. The primary outcome, degree of blanching, B, is computed as B = (fB1-fB2)/fB1.
Interventions
- DEVICE Pulsed Dye Laser
- DEVICE Combined Bipolar Radiofrequency&Pulsed Dye Laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-08 |
| Phase | NA |
What the finished NCT01775722 record still lists
NCT01775722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Pulsed Dye Laser is the first listed.
NCT01775722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01775722 about?
NCT01775722 is a clinical study titled "Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment". Port wine stain Birthmark is a congenital, progressive vascular malformation of human skin. However, even though the pulsed dye laser is considered as the treatment of choice for Port wine stain Birthmark the degree of fading can remain variable and unpredictable after laser treatment.
What is the current status of trial NCT01775722?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2012-12. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01775722?
The interventions under investigation include: Pulsed Dye Laser (DEVICE), Combined Bipolar Radiofrequency&Pulsed Dye Laser (DEVICE).
Who is sponsoring clinical trial NCT01775722?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01775722's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia